MAEBL

MAEBL (PF3D7_1147800) is a type I transmembrane, chimeric erythrocyte-binding protein that acts as an adhesive ligand across multiple Plasmodium life-cycle stages (PMID:9448314, PMID:12021311, PMID:28371168). Its ectodomain is a mosaic in which an N-terminal cysteine-rich region resembles AMA-1 domains I/II arranged as two tandem ligand modules (M1 and M2), while its C-terminal region is homologous to the EBL family (PMID:9448314). Both AMA-1-like domains bind erythrocytes in vitro, and the M2 domain engages a papain-sensitive, sialic acid-independent red-cell receptor (PMID:9448314, PMID:12165387). In merozoites, MAEBL transits the classical secretory pathway to rhoptry organelles and co-localizes with rhoptry proteins, where it is proteolytically processed such that the amino cysteine-rich ligand domains are shed while the transmembrane-proximal carboxyl domain is retained; its transmembrane segment is an efficient and selective substrate for the intramembrane rhomboid protease PfROM4 but not PfROM1 (PMID:10838220, PMID:12076768, PMID:17040128). Blood-stage MAEBL is dispensable for erythrocytic growth in vitro (PMID:15811533). In sporozoites the protein localizes to micronemes and the parasite surface and is essential for attachment to and invasion of the mosquito salivary gland, an activity that requires specifically the transmembrane isoform (PMID:12021311, PMID:18509478, PMID:35628522). MAEBL additionally mediates sporozoite cell traversal, hepatocyte adhesion, and liver-stage invasion, phenotypes rescued by genetic complementation (PMID:28371168, PMID:35628522). Its expression and isoform composition are developmentally controlled through conserved alternative splicing that toggles between membrane-bound and predicted soluble forms, and through a bicistronic transcript architecture with an exceptionally long 5'-UTR harboring an upstream ORF (PMID:15155670, PMID:15465047, PMID:18950624).

1. 1998 Medium

   Establishing that MAEBL is a chimeric adhesin answered what kind of ligand it is: an AMA-1/EBL mosaic whose tandem AMA-1-like domains, not Duffy-binding-like domains, mediate erythrocyte binding.

   Evidence In vitro erythrocyte-binding of recombinant M1/M2 domains expressed in COS cells with sequence/domain analysis and IFA, in P. yoelii and P. berghei orthologues

   PMID:9448314

   Open questions at the time

   • Native receptor on the erythrocyte not identified
   • Binding of full-length native protein versus isolated domains not established
2. 1998 Medium

   Co-localization with rhoptry markers and timing of appearance placed MAEBL in the merozoite apical secretory machinery, distinguishing it biochemically from soluble DBL-EBP adhesins.

   Evidence IFA co-localization with AMA-1 and 235 kDa rhoptry proteins, immunoprecipitation and Western blot in P. yoelii YM

   PMID:9851604

   Open questions at the time

   • Functional role in the rhoptry not tested
   • Basis of the ~120/128 kDa doublet not defined
3. 2000 Medium

   Tracing MAEBL through ER, Golgi, and rhoptry precursors defined its trafficking route to the apical organelles during schizogony.

   Evidence Live and fixed IFA with ER and Golgi markers across schizont differentiation in P. yoelii

   PMID:10838220

   Open questions at the time

   • Trafficking signals/sorting determinants not mapped
   • Single-species observation
4. 2002 High

   Knockout in P. berghei answered which life-cycle step requires MAEBL, showing it is essential for sporozoite invasion of the mosquito salivary gland but dispensable for motility and vertebrate infectivity as assayed.

   Evidence Targeted gene disruption with salivary gland invasion and motility assays plus microneme IFA in P. berghei

   PMID:12021311

   Open questions at the time

   • Salivary gland receptor for MAEBL unknown
   • Mechanistic step of attachment versus invasion not separated
5. 2002 Medium

   Reciprocal co-localization and fractionation in P. falciparum showed MAEBL associates with rhoptry (not microneme) proteins in merozoites and is processed so ligand domains are shed while the membrane-proximal domain is retained.

   Evidence IFA co-localization with RhopH2/RAP-1 versus EBA-175/BAEBL and Western blot of supernatant versus detergent fractions in P. falciparum

   PMID:12076768

   Open questions at the time

   • Protease responsible for ectodomain shedding not identified here
   • Functional consequence of shedding untested
6. 2002 Medium

   Enzymatic dissection of M2-domain binding defined the receptor as protease-sensitive and sialic-acid-independent, refining the biochemical nature of MAEBL-erythrocyte engagement.

   Evidence Recombinant PfM2 erythrocyte-binding assay with papain/neuraminidase treatments plus IFA in P. falciparum

   PMID:12165387

   Open questions at the time

   • Molecular identity of the receptor not determined
   • Only M2 tested for receptor properties
7. 2003 Medium

   Stage-resolved imaging showed MAEBL redistributes from storage organelles to the sporozoite surface as oocysts mature, linking its relocation to acquisition of salivary-gland invasiveness.

   Evidence IFA at defined oocyst developmental time-points in P. berghei

   PMID:14627711

   Open questions at the time

   • Trigger for redistribution unknown
   • Correlative rather than causal link to invasion
8. 2004 Medium

   Isoform mapping revealed that salivary gland sporozoites uniquely express a full-length membrane form retaining both M1 and M2 domains, and antibodies to these domains block sporozoite development, implicating the ligand domains functionally.

   Evidence Stage-specific Western blots and antibody inhibition of exoerythrocytic development in P. berghei

   PMID:15155670

   Open questions at the time

   • Direct target of the inhibitory antisera in the invasion pathway not defined
   • Whether M1 and M2 have distinct functions unresolved
9. 2004 Medium

   Peptide scanning localized erythrocyte-binding activity to discrete high-activity regions across M1, M2, and the repeat region and tied binding to a 33 kDa red-cell membrane protein.

   Evidence Synthetic peptide binding assays, merozoite invasion inhibition, and RBC membrane protein binding in P. falciparum

   PMID:14766210

   Open questions at the time

   • 33 kDa RBC protein not identified
   • Peptide-level binding may not reflect native domain architecture
10. 2004 Medium

    Discovery of conserved, developmentally controlled alternative splicing showed the maebl locus can produce either the type I membrane protein or a predicted soluble isoform, providing a regulatory switch over MAEBL form.

    Evidence RT-PCR, Western blot, and splice-variant sequence analysis across P. falciparum, P. berghei, and P. yoelii

    PMID:15465047

    Open questions at the time

    • Regulators of splice-site choice unknown
    • Function of the soluble isoform not directly tested here
11. 2005 Medium

    Knockout in P. falciparum established that blood-stage MAEBL is not required for erythrocytic growth in vitro, narrowing its essential roles to other stages.

    Evidence Targeted gene disruption in P. falciparum (abstract-level)

    PMID:15811533

    Open questions at the time

    • Abstract only, limited methodological detail
    • Possible redundancy with other invasion ligands not examined
12. 2006 High

    Identifying MAEBL as a selective PfROM4 substrate provided a molecular mechanism for membrane release/processing, dependent on the MAEBL transmembrane domain.

    Evidence Heterologous rhomboid cleavage assay with transmembrane-domain swaps in P. falciparum

    PMID:17040128

    Open questions at the time

    • In vivo timing and requirement of PfROM4 cleavage of MAEBL not shown
    • Functional consequence of cleavage for invasion untested
13. 2008 High

    Isoform-specific allelic replacement demonstrated that only the transmembrane MAEBL isoform supports salivary gland invasion, assigning function to a specific molecular form.

    Evidence Knockout and single-isoform allelic replacement with salivary gland invasion assays in P. falciparum NF54

    PMID:18509478

    Open questions at the time

    • Role, if any, of the soluble isoform not defined
    • Molecular partner engaged by the transmembrane form unknown
14. 2008 Medium

    Mapping the maebl mRNA revealed a bicistronic architecture with a >2 kb 5'-UTR containing an upstream ORF and an upstream minimal promoter, defining an unusual transcriptional/translational control layer.

    Evidence Northern blot, RT-PCR, 5'-RACE, and transient CAT reporter assays in P. falciparum

    PMID:18950624

    Open questions at the time

    • Regulatory function of the upstream ORF not established
    • Translational control mechanism not defined
15. 2017 High

    Knockout with complementation in P. falciparum uncovered a distinct essential role for MAEBL in sporozoite cell traversal and hepatocyte invasion, extending its function beyond salivary gland entry into liver-stage infection.

    Evidence Gene knockout with genetic complementation, cell traversal and hepatocyte invasion assays, and humanized chimeric liver mouse infection in P. falciparum

    PMID:28371168

    Open questions at the time

    • Hepatocyte receptor/ligand for MAEBL not identified
    • Mechanistic distinction between traversal and productive invasion not resolved
16. 2022 High

    Knockout/complementation in P. berghei consolidated MAEBL's role in hepatocyte adhesion, gliding motility, wounding, and invasion, and showed stage-dependent surface/microneme localization with declining levels after salivary gland entry.

    Evidence Transgenic knockout and complemented parasites, live mouse imaging, hepatocyte adhesion/invasion, gliding and wounding assays, and myc-tagged MAEBL IFA in P. berghei

    PMID:35628522

    Open questions at the time

    • Molecular basis of adhesion to hepatocytes unknown
    • Cause of post-salivary-gland decline in MAEBL not defined

• The molecular identities of the MAEBL receptors on erythrocytes, mosquito salivary glands, and hepatocytes, and the in vivo role of PfROM4 cleavage, remain unresolved.
• No host receptor for any MAEBL-dependent invasion step has been molecularly identified
• In vivo functional requirement and timing of PfROM4 processing of MAEBL untested
• Function of the soluble spliced isoform undefined